No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Positive Signs As Multiple Insiders Buy Savara Stock
Savara's Molgramostim: Strong Buy Rating Backed by Clinical and Real-World Evidence for APAP Treatment
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) Published in ERJ Open Research
Savara Announces Participation in Upcoming Healthcare Investor Conferences
Savara Sets 2025 Executive Bonus Targets
Is Savara (NASDAQ:SVRA) A Risky Investment?